Can AXTI Deliver Its Biggest Indium Phosphide Quarter Ever?

AXT said Q2 Indium Phosphide revenue could exceed its prior quarterly record, supported by a backlog above $100 million and about $34 million already secured for the quarter. Management also expects China-related Indium Phosphide revenue to double again in the current quarter, driven by strong AI infrastructure and optical networking demand despite export restrictions. Peer commentary from MKS Instruments and ASE Technology was also constructive, with both citing AI-driven semiconductor spending and raised outlooks.

Analysis

AXTI is effectively becoming a high-beta call option on AI optical interconnect intensity, but the market is now pricing it as if that demand is both durable and frictionless. The second-order winner is not just AXTI’s wafer revenue; it is the broader non-US, non-leading-edge supply chain that can monetize AI networking capex without needing to win node transitions. That said, the biggest embedded risk is execution under export-control variability: permit timing can shift revenue by a quarter, which means the stock can remain extremely gap-prone even if the multi-quarter demand story is intact.

For MKSI, the more important signal is that the AI capex cycle is broadening from “leading-edge compute” into the process tooling and photonics layer. That tends to extend cycle duration because it is less dependent on one customer cohort and more tied to equipment install cadence across several end markets. The risk is that the market extrapolates a straight-line upcycle into 2H26, while tool demand historically decelerates abruptly if memory/logic capex discipline tightens or if customers pull forward fewer orders after capacity comes online.

ASX looks like the highest-quality beneficiary structurally, but the market may be underestimating how much of the near-term upside is already in advanced packaging expectations. If LEAP ramps as promised, the real earnings inflection is likely to be more visible in 2026-2027 than in the next 1-2 quarters, which argues for patience rather than chasing strength. The contrarian view is that AXTI’s 29.5x sales multiple leaves little room for any permit delay, customer mix deterioration, or China policy shock; that valuation is more consistent with perfect execution than with a business still exposed to sanctions friction.

Key Decisions for Investors

• Maintain a tactical long AXTI, but only via call spreads or a capped-risk structure into the next permit update: favorable skew if approvals accelerate, but downside is severe if shipment timing slips by even one quarter.
• Pair long MKSI / short a weaker capital-equipment laggard over a 3-6 month horizon: MKSI has the cleaner exposure to AI-driven breadth in semiconductor capex and should out-earn peers if the upcycle extends into late 2026.
• Add ASX on pullbacks for a 6-12 month hold rather than chasing momentum: the setup is better for compounding as LEAP capacity ramps, with limited near-term downside if advanced packaging demand stays firm.
• Consider a relative-value short AXTI vs long ASX basket if the market begins to rotate from scarcity premium to durable earnings quality: AXTI has the most valuation fragility, while ASX has the more credible multi-year ramp.
• Set a tight risk stop on any AXTI outright long: if next-quarter revenue visibility deteriorates or export permit conversion disappoints, the multiple can compress quickly despite still-strong underlying demand.